Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.33 |
| ▸ | CNR1 | P21554 | 6/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21720048 | 1.00 | CNR2 (0.33) | CNR2CNR1KDM4ETP53CYP3A4 | |
| SCHEMBL21719608 | 0.82 | KDM4E (0.30) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL21719762 | 0.82 | SMPD1 (0.30) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL21720049 | 0.82 | CCNB2 (0.33) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL21719618 | 0.82 | GGPS1 (0.33) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL21720043 | 0.81 | KDM4E (0.40) | CNR2CNR1KDM4ETP53CYP3A4 | |
| SCHEMBL21969698 | 0.81 | — | — | |
| SCHEMBL21884282 | 0.81 | CNR1 (0.35) | CNR2CNR1KDM4ETP53CYP3A4 | |
| SCHEMBL21885502 | 0.77 | ALDH1A1 (0.32) | CNR2CNR1KDM4ETSHR | |
| SCHEMBL21718616 | 0.77 | CNR2 (0.33) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | CNR2 187/4885CNR1 238/4885KDM4E 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.